According to Reuters, Lilly could offer the lowest dose of its popular weight loss drug Zepbound at $149 a month, and Novo’s ...

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year forecasts on Wednesday as sales growth of its ...

Novo Nordisk stock slid Wednesday after the Danish drugmaker’s third-quarter results missed estimates, and it trimmed its ...

The White House is nearing an agreement with pharmaceutical companies Novo Nordisk and Eli Lilly to offer some of their ...

Third-quarter results will be the first for Mike Doustdar who was tasked in August with turning around the Danish company's ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock are in focus as the companies are nearing to strike U.S. pricing deals for ...

Eli Lilly and Company (NYSE:LLY) shares are trading slightly lower on Tuesday after its previous gains following reports ...

Novo Nordisk has cut its outlook for 2025 as lower expectations for glucagon-like peptide-1 receptor agonists (GLP-1RA) continue to hit the drugmaker. Net profit for Q3 came in at Dkr20bn ($3.1bn), ...

Record performance of its GLP-1 drugs sent shares in Eli Lilly soaring almost 4% after its earnings call on Thursday.